STOCKS TELEGRAPH

Tag: TBIO

  • Telesis Bio (TBIO) Surge: Unraveling the Mystery Behind the Meteoric Rise

    In an unexpected turn of events, Telesis Bio, Inc. (NASDAQ: TBIO) witnessed an extraordinary surge in its stock price, sending shockwaves through the market. The company’s shares soared by an unprecedented 99% during after-hours trading, following a remarkable 30% climb in the regular session. This surge, accompanied by an astonishing volume of 17 million shares changing hands, has left investors both exhilarated and cautious about what lies ahead.

    Speculation Without Substantiation

    One of the most intriguing aspects of this surge is the absence of any significant news catalyst. While market analysts scramble to make sense of the sudden uptick, many remain puzzled by the lack of concrete information driving the rally. Some speculate that insider knowledge or undisclosed developments may be fueling investor optimism, while others fear the possibility of a speculative frenzy leading to a potential market downturn.

    Financial Realities and Future Projections

    In its recent financial report, Telesis Bio disclosed a third-quarter loss of $10.6 million, equivalent to a loss of 37 cents per share. Although the company generated revenue of $5.6 million during the period, it fell short of analysts’ expectations, who had anticipated revenues of $7.4 million. Despite this setback, Telesis Bio remains steadfast in its optimism, projecting full-year revenue to range between $28 million to $30 million.

    Anticipation Builds Ahead of Financial Disclosures

    As investors eagerly await the upcoming announcement of the fourth-quarter and full-year results, anticipation continues to build regarding the company’s financial performance and its strategic outlook. Analysts and investors alike are keen to gain insights into Telesis Bio’s ability to capitalize on its multi-omic and synthetic biology solutions amidst a rapidly evolving market landscape.

    Conclusion

    Telesis Bio’s recent stock surge has captured the attention of the market, defying expectations and sparking intense speculation. While the absence of concrete news leaves room for uncertainty, investors remain cautiously optimistic about the company’s prospects moving forward. As the wait for further financial disclosures continues, all eyes remain firmly fixed on Telesis Bio and its journey in the dynamic world of synthetic biology.

  • Translate Bio Inc. (TBIO) stock is plummeting 22%, Here’s what you should know

    Translate Bio Inc. (TBIO) stock is plummeting 22%, Here’s what you should know

    The Translate Bio Inc. (TBIO) stock lost 22.10% in the pre-market trading on Thursday, March 18 2021 after TBIO announced the clinical trial results of its RNA drug. The negativity continuous in the pre-market session as of this writing and it lost a further 25.10%.

    TBIO shared the news with the market yesterday March 17, 2021, and according to the results RNA drug failed to improve lung function in cystic fibrosis patients and the news sent TBIO stock plummeting.

    Although no adverse reaction was noted except mild to moderate symptoms of a febrile reaction such as fever, headache and chills occurred in three patients after the first dose of MRT5005 and it didn’t improve lung function.

    Translate Bio Chief Medical Officer Ann Barbieris still hopeful and said that based on the first and second interim analyses. TBIO stock has achieved a safety profile that supports repeat dosing of inhaled mRNA and further advancement of the pulmonary platform for chronic dosing.

    Cystic fibrosis is the most common fatal inherited disease in the United States, affecting more than 30,000 patients in the U.S. and more than 70,000 patients worldwide.

    COVID-19 Vaccine update

    On March 15, 2021, Translate Bio and its partner Sanofi showed their initiation of a phase I/II study on their mRNA-based vaccine candidate, MRT5500, to check the vaccine’s safety & immune response. Companies are looking to enroll 415 adults. Trial data is expected to be available in the third quarter of 2021.

    Granting non-qualified stock options

    On March 3, 2021, TBIO stock told that it has granted non-qualified stock options to purchase an aggregate of 54,250 shares, for $23.80 per share of TBIO’s common stock to seven newly hired employees.

    About TBIO

    TBIO is developing a revolutionary class of potential medicines, based on mRNA, to treat or prevent debilitating or life-threatening diseases. TBIO was founded in 2001 and its headquarter is in Lexington, Massachusetts, United States. TBIO  has its own mRNA therapeutic platform (MRT) and is using to treat pulmonary diseases caused by insufficient protein production or where the production of proteins can modify disease.